buyModerate
Norbert W Bischofberger bought $734k of KRON
PRESIDENT & CEO at Kronos Bio, Inc.. 615,518 shares at an average of $1.19, traded Jun 27, 2024, filed Jul 1, 2024.
Conviction score
54Value
$734k
615,518 shares
Holdings after
10,802,138
+6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +21Trade size$734k at market
- +3Relative to holdingsHoldings up 6%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-018703, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 27, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +410,848 | $1.17 | $479k | 10,597,468 | Jul 1, 2024 |
| Jun 28, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +204,670 | $1.25 | $255k | 10,802,138 | Jul 1, 2024 |
Related signals
Other insiders at Kronos Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | KRONsell Kronos Bio, Inc. | Deborah Knobelman President & Interim CEO | $22k 24,838 shares | -15% | |
| 60Notable | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $3.1M 3,005,122 shares | +69% | |
| 30Weak | Kronos Bio, Inc. | Allison Frisbee SR VP, CORP OPERATIONS & LEGAL | $13k 12,105 shares | -6% | |
| 30Weak | Kronos Bio, Inc. | Charles Y Lin SR VP, RESEARCH & DEVELOPMENT | $13k 12,036 shares | -5% | |
| 30Weak | Kronos Bio, Inc. | Elizabeth A Olek SR VP, CLINICAL SCIENCE | $7,765 7,368 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $14k 12,009 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $8,718 7,366 shares | -3% | |
| 35Weak | Kronos Bio, Inc. | Barbara Kosacz COO & General Counsel | $13k 10,676 shares | -1% | |
| 23Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $23k 17,367 shares | -5% | |
| 23Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $13k 10,032 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.